Mario Sznol MD

Professor of Medicine (Medical Oncology); Clinical Research Program Leader, Melanoma Program, Yale Cancer Center; Co-Director, Yale SPORE in Skin Cancer

Specialties & Subspecialties

Cancer Center, Yale: Prostate and Urologic Cancers Program | Melanoma Program

Medical Oncology

General Urology

Medical Oncology

Education & Training

  • B.A., Rice University (1979)
  • M.D., Baylor College of Medicine (1982)
  • Resident, Baylor College of Medicine , Internal Medicine 
  • Fellow, Mount Sinai College of Medicine , Medical Oncology 

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

melanoma; immunologic therapy; renal cell (kidney) carcinoma; Phase I trials


Cancers Treated

Kidney, Melanoma, Renal


Board Certifications

  • Internal Medicine, Board Certified (1985)
  • Medical Oncology, Board Certified (1987)

Clinical Trials

Conditions Study Title
Breast Cancer (ER, PR, and HER2 negative), Colorectal Cancer, Endometrial Cancer, Gastric Adenocarcinoma, Glioblastoma Multiforme, Head/ Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Prostate Cancer, Brain and Nervous System, Breast - Female, Breast - Male, Colon, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Female Genital, Ovary, Prostate, Rectum, and Stomach A Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Lung and Melanoma, skin A Phase 2 Study of MK-3475 in patients with metastatic melanoma and non-small cell lung cancer with untreated brain metastases
Kidney A PHASE II, RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA
Expanded Access of MK-3475 in Metastatic Melanoma Patients with Limited to No Treatment Options
A phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has progressed after prior VEGFR Tyrosine Kinase Inhibitor Therapy

More Clinical Trials...

Edit Profile